News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ABPI recent news/filings
bullish
charts that are focused on long term growth and are not affected by earnings reports
## source: finance.yahoo.com
no recent news found
*********************************************************
$ABPI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ABPI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ABPI/company-info
Ticker: $ABPI
OTC Market Place: OTC Pink No Information
CIK code: 0001310094
Company name: Accentia Biopharmaceuticals, Inc.
Incorporated In: FL, USA
Business Description: Accentia Biopharmaceuticals, Inc. is engaged in the business of commercializing patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID., a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune(c), a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase(c), a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.Additionally, Accentia's wholly-owned subsidiary, Analytica International, markets pharmaceutical consulting services.Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. and Accentia also maintains a royalty interest in Biovest's biologic products. Accentia is a portfolio company of the Hopkins Capital Group.Less >>
$ABPI share structure
## source: otcmarkets.com
Market Value: $421,853 a/o Jul 27, 2015
Shares Outstanding: 89,755,901 a/o Jan 31, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ABPI extra dd links
Company name: Accentia Biopharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ABPI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ABPI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ABPI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/news - http://finance.yahoo.com/q/h?s=ABPI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ABPI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ABPI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ABPI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accentia+Biopharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accentia+Biopharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accentia+Biopharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ABPI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001310094&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ABPI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ABPI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ABPI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ABPI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ABPI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ABPI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ABPI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ABPI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ABPI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ABPI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ABPI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ABPI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ABPI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ABPI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ABPI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ABPI
$ABPI DD Notes ~ http://www.ddnotesmaker.com/ABPI
$ABPI DD Notes ~ http://www.ddnotesmaker.com/ABPI
Topdown market analysis:
Market is _BULLISH_
Today is _UP_
Bullish Sector _BIOTECHNOLOGY_
bullish stock in this sector
$ABPI recent news/filings
## source: finance.yahoo.com
no recent news found
*********************************************************
$ABPI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ABPI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ABPI/company-info
Ticker: $ABPI
OTC Market Place: OTC Pink No Information
CIK code: 0001310094
Company name: Accentia Biopharmaceuticals, Inc.
Incorporated In: FL, USA
Business Description: Accentia Biopharmaceuticals, Inc. is engaged in the business of commercializing patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID., a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune(c), a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase(c), a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.Additionally, Accentia's wholly-owned subsidiary, Analytica International, markets pharmaceutical consulting services.Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. and Accentia also maintains a royalty interest in Biovest's biologic products. Accentia is a portfolio company of the Hopkins Capital Group.Less >>
$ABPI share structure
## source: otcmarkets.com
Market Value: $601,365 a/o Oct 29, 2014
Shares Outstanding: 89,755,901 a/o Jan 31, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ABPI extra dd links
Company name: Accentia Biopharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ABPI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ABPI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ABPI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/news - http://finance.yahoo.com/q/h?s=ABPI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ABPI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ABPI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ABPI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accentia+Biopharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accentia+Biopharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accentia+Biopharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ABPI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001310094&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ABPI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ABPI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ABPI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ABPI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ABPI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ABPI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ABPI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ABPI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ABPI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ABPI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ABPI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ABPI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ABPI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ABPI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ABPI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ABPI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ABPI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ABPI
$ABPI DD Notes ~ http://www.ddnotesmaker.com/ABPI
|
Followers
|
28
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
677
|
|
Created
|
09/03/05
|
Type
|
Free
|
| Moderators | |||
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have entered into a Cooperative Research and Development Agreement (CRADA) to further develop Biovest’s hollow fiber perfusion bioreactors as a flexible and modular manufacturing platform for the rapid, robust and cost-effective production of medical countermeasures to emerging and genetically engineered infectious diseases. This CRADA utilizes Biovest’s hollow fiber technology for production of vaccines, virus-like particles (VLPs) and antibodies for treatment and prevention of filovirus diseases including those caused by Ebola and Marburg viruses.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID”
According to Biovest’s consulting medical advisor, J. David Gangemi, Ph.D., Professor Emeritus, Microbiology and Molecular Medicine, Clemson University, “Biovest’s collaboration with USAMRIID is part of a large U.S. government priority investment to become fully prepared for the swift and efficient delivery of medical countermeasures to highly infectious agents including avian and swine influenza, and other emerging diseases. Expanding on the positive influenza virus data generated under Biovest’s CRADA with the Naval Health Research Center, our collaboration with Army’s infectious disease research team aims to demonstrate the utility and agility of Biovest’s hollow fiber bioreactors to propagate infectious virus for vaccine production and to validate the production of VLPs and virus neutralizing antibodies.”
Biovest’s patented hollow fiber bioreactor systems are compact, scalable and economical for large-scale virus and antibody production. In contrast to other systems, Biovest’s technology provides multiple benefits including: 1) controlled culture conditions with high cell density attained; 2) space efficiency and high-yield production; and 3) selective dilution/removal of inhibitory byproducts.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID,” stated, Biovest’s Chief Science Officer, Mark Hirschel, Ph.D. “And we are continuing to pursue other strategic partnerships within the U.S. Department of Defense and with other leading research institutions worldwide to establish Biovest’s biomanufacturing technology as an optimal cell culture platform for the production of many kinds of cell-based biologic therapies.”
AutovaxID® is an automated, self-contained, scalable system that employs a single-use, hollow-fiber bioreactor for cell expansion. Since it is functionally closed, computer-controlled and fully-automated, operation of the AutovaxID requires limited supervision and minimal manpower compared to other systems. The AutovaxID is a flexible system, uniquely designed to address a variety of biotechnology and pharmaceutical applications.
Been in development for over 2 YEARS. This company has been in the development a treatment for over 2 years, much more than those JUST OTC companies coming into the market just now.MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--
Biovest International, Inc. (“Biovest”), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest’s Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate’s Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled “The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines”, and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies”, and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development – Examining Trial Designs and Biomarker R&D Strategies – Case Study 3”.
“This forum provides us an excellent opportunity to advance personalized immunotherapy and interact with leaders in the fields of cancer vaccines, cell and gene therapy, and biologics manufacturing,” said Dr. Santos. “At Biovest, we have developed a highly personalized, tumor-matched cancer vaccine (BiovaxID; dasiprotimut-T) to fight non-Hodgkin’s lymphoma. As part of our efforts in bringing this vaccine to market, we have also pioneered highly automated systems for biomanufacturing of personalized medicines. We believe these advances, together with the clinical informatics and biomarker data which accompanies each of our vaccines, will ultimately make cancer vaccines much more accessible for patients diagnosed with non-Hodgkin’s lymphoma.”
Robert E. Farrell, J.D., Biovest’s Chief Financial Officer, will be presenting at the Personalized Medicines World Conference of Silicon Valley on January 27-28, 2014. Mr. Farrell’s presentation, “Automated Systems for Personal-Scale Manufacture of Commercial Cancer Vaccines“, will take place on January 28, 2014 at 8:45 AM PST at the Computer History Museum in Mountain View, CA. Mr. Farrell stated, “both of these conferences will present substantial exposure for Biovest’s immunotherapy program and provide an exciting opportunity to network with the biotechnology, personalized medicine, active immunotherapy, and investment communities. They provide outstanding venues in which to display our pioneering advances in personalized cancer vaccines.”
About Biovest International, Inc.
Biovest International, Inc. develops autologous active immunotherapies (personalized cancer vaccines) to treat B-cell non-Hodgkin’s lymphomas, which are cancers of the immune system. The Company’s lead personalized cancer vaccine candidate, BiovaxID, has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxID’s ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxID.
Accentia Biopharmaceuticals, Inc., a biotechnology company, engages in the development and commercialization of biopharmaceutical products in the United States. It develops Cyrevia as a system of care for the treatment of autoimmune diseases; SinuNasal lavage system as a medical device for the treatment of chronic sinusitis; and BiovaxID as a personalized therapeutic cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, mantle cell lymphoma, and other B-cell cancers. The company also sells hollow-fiber perfusion instruments used for the production of significant quantities of cell culture products, including AutovaxID, an automated cell culture production instrument an instrument for the production of cancer vaccines and other personalized medicines; Primer HF, a hollow-fiber cell culture system for producing small quantities of monoclonal antibody; miniMax and Maximizer for use in the production of mammalian cell secreted proteins; XCellerator, a self-standing floor system to support production protein; Multi-6, a cell culture system for producing six monoclonal antibodies; and hollow-fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. It has collaboration with the United States Department of Defense to develop AutovaxID and to explore potential production of additional vaccines, including vaccines for viral indications, such as influenza. The company was founded in 2002 and is headquartered in Tampa, Florida.
